RecruitingPhase 2NCT05950594

IVIM & OLINK in Sarcoma

Prospective Study of Image and Blood-derived Biomarkers to Predict Metastasis in Soft-tissue Sarcomas

Sponsor

University Health Network, Toronto

Enrollment

145 participants

Start Date

Mar 5, 2024

Study Type

INTERVENTIONAL

Conditions

Soft Tissue Sarcoma

Summary

The hypoxia \> metastasis axis suggests that a DWI-based biomarker of hypoxia incorporating IVIM may be able to predict metastasis in STS patients, ultimately enabling stratification for personalized treatments at the time of diagnostic (MR) imaging, without adding an excessive burden to the patient or clinical workflow (typical DWI/IVIM sequences can be acquired acquired in approximately 5 minutes).

Eligibility

Min Age: 18 YearsMax Age: 100 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating the use of a specialized MRI technique (called IVIM) and a blood protein panel (called OLINK) to better understand and characterize soft tissue sarcomas. The goal is to identify new biomarkers that may help doctors diagnose, classify, and track the progression of sarcoma more accurately. **You may be eligible if...** - You are 18 or older - You have a Grade 2 or 3 soft tissue sarcoma (a type of cancer that forms in connective tissues such as muscle or fat) that is larger than 5 cm - You are willing and able to provide written informed consent **You may NOT be eligible if...** - You have a contraindication to MRI scanning (such as certain metal implants or a pacemaker) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.